Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma

被引：39

作者：

Demierre, MF

Kim, YH

Zackheim, HS

机构：

[1] Boston Univ, Sch Med, Dept Dermatol & Med, Boston, MA 02118 USA

[2] Stanford Univ, Ctr Med, Dept Dermatol, Stanford, CA 94305 USA

[3] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94115 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2003年 / 17卷 / 06期

关键词：

D O I：

10.1016/S0889-8588(03)00111-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For physicians who are caring for patients who have cutaneous T-cell lymphoma (CTCL), knowledge of prognostic factors is relevant. Additional considerations should be given to the choice of therapy and quality of life issues. This article reviews methodologic issues in studies of prognosis and survival, emphasizes important endpoints as measures of outcome to treatments of mycosis fungoides (MF)/Sezary syndrome (SS), the most common form of CTCL, and discusses approaches to assessing the quality of life (QOL) of patients. QOL instruments that could be incorporated in clinical trials of therapies for patients who have MF/SS are reviewed.

引用

收藏

页码：1485 / +

页数：24

相关论文

共 118 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2] ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].

ANDERSON, JR ;

CAIN, KC ;

GELBER, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719

[3] GUIDELINES FOR REPORTING OUTCOMES OF LYMPHOMA TRIALS [J].

ANDERSON, JR ;

PROPERT, KJ ;

HARRINGTON, DP .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :559-560

[4]

[Anonymous], 1996, J Clin Oncol, V14, P671

[5]

Beitz J, 1996, J Natl Cancer Inst Monogr, P7

[6] Primary and secondary cutaneous CD30+ lymphoproliferative disorders:: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment [J].

Bekkenk, MW ;

Geelen, FAMJ ;

Vader, PCV ;

Heule, F ;

Geerts, ML ;

van Vloten, WA ;

Meijer, CJLM ;

Willemze, R .

BLOOD, 2000, 95 (12) :3653-3661

[7] Prognostic factors in Sezary syndrome: A multivariate analysis of clinical, haematological and immunological features [J].

Bernengo, MG ;

Quaglino, P ;

Novelli, M ;

Cappello, N ;

Doveil, GC ;

Lisa, E ;

De Matteis, A ;

Fierro, MT ;

Appino, A .

ANNALS OF ONCOLOGY, 1998, 9 (08) :857-863

[8] Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: A 9-year retrospective study at a single institution [J].

Bisaccia, E ;

Gonzalez, J ;

Palangio, M ;

Schwartz, J ;

Klainer, AS .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (02) :263-271

[9] Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system [J].

Bonomi, AE ;

Cella, DF ;

Hahn, EA ;

Bjordal, K ;

SpernerUnterweger, B ;

Gangeri, L ;

Bergman, B ;

WillemsGroot, J ;

Hanquet, P ;

Zittoun, R .

QUALITY OF LIFE RESEARCH, 1996, 5 (03) :309-320

[10] Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma [J].

Breneman, D ;

Duvic, M ;

Kuzel, T ;

Yocum, R ;

Truglia, J ;

Stevens, VJ .

ARCHIVES OF DERMATOLOGY, 2002, 138 (03) :325-332

← 1 2 3 4 5 6 7 8 9 10 →